Literature DB >> 9671688

Optimal effectiveness of BDNF for fetal nigral transplants coincides with the ontogenic appearance of BDNF in the striatum.

D M Yurek1, S B Hipkens, S J Wiegand, C A Altar.   

Abstract

Transplantation of fetal nigral dopamine neurons into the caudate and putamen of Parkinson's disease patients produces limited symptomatic relief. One approach to augment the outgrowth and function of nigral grafts includes exposure of the graphs to neurotrophic factors; however, the temporal requirements for optimizing these actions are unknown. The present study characterized the ontogeny of brain-derived neurotrophic factor (BDNF) in the rat striatum and used this information to define and evaluate three distinct periods of BDNF infusion into fetal nigral grafts transplanted into the striatum of rats with experimental Parkinson's disease. At postnatal day 1 (P1), BDNF and dopamine were measured at 17 and 27% of peak levels, respectively, that occurred at P27 for both. Both compounds showed their greatest surge between P7 and P20, increasing from 40% to approximately 95% of peak levels. Exogenous BDNF infused into transplants during weeks 1 and 2 after the transplantation, which coincide with the developmental period embryonic day 14 (E14)-P7 for transplanted tissue, did not improve rotational behavior or enhance fiber outgrowth of transplanted dopamine neurons. Delaying the BDNF infusion until transplanted tissue was approximately P8-P21 greatly enhanced the effect on rotational behavior and doubled the area of dopamine fiber outgrowth from the transplants. Delaying the infusion until transplanted tissue was approximately P36-P49 failed to augment fiber outgrowth and decreased the behavioral function of transplants. Thus, the optimal effect of exogenous BDNF on the development of dopamine neurons in fetal nigral transplants occurs at a postnatal age when endogenous dopamine and BDNF show the greatest increases during the normal development of the striatum.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671688      PMCID: PMC6793048     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  38 in total

1.  Acidic and basic fibroblast growth factors augment growth of fetal brain tissue grafts.

Authors:  M M Giacobini; B J Hoffer; G Zerbe; L Olson
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

2.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra.

Authors:  C Hyman; M Hofer; Y A Barde; M Juhasz; G D Yancopoulos; S P Squinto; R M Lindsay
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

Review 3.  The nerve growth factor family of receptors.

Authors:  S O Meakin; E M Shooter
Journal:  Trends Neurosci       Date:  1992-09       Impact factor: 13.837

4.  GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats.

Authors:  Y Wang; L T Tien; P A Lapchak; B J Hoffer
Journal:  Cell Tissue Res       Date:  1996-11       Impact factor: 5.249

Review 5.  Function and evolution in the NGF family and its receptors.

Authors:  T Ebendal
Journal:  J Neurosci Res       Date:  1992-08       Impact factor: 4.164

Review 6.  The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.

Authors:  R M Lindsay; C A Altar; J M Cedarbaum; C Hyman; S J Wiegand
Journal:  Exp Neurol       Date:  1993-11       Impact factor: 5.330

7.  Brain-derived neurotrophic factor enhances function rather than survival of intrastriatal dopamine cell-rich grafts.

Authors:  H Sauer; W Fischer; G Nikkhah; S J Wiegand; P Brundin; R M Lindsay; A Björklund
Journal:  Brain Res       Date:  1993-10-29       Impact factor: 3.252

8.  Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease.

Authors:  H Takayama; J Ray; H K Raymon; A Baird; J Hogg; L J Fisher; F H Gage
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

9.  Brain-derived neurotrophic factor and neurotrophin-3 mRNAs are expressed in ventral midbrain regions containing dopaminergic neurons.

Authors:  C M Gall; S J Gold; P J Isackson; K B Seroogy
Journal:  Mol Cell Neurosci       Date:  1992-02       Impact factor: 4.314

10.  Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons--I. Effects in vitro.

Authors:  E Mayer; S B Dunnett; R Pellitteri; J W Fawcett
Journal:  Neuroscience       Date:  1993-09       Impact factor: 3.590

View more
  5 in total

Review 1.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

2.  The brain-derived neurotrophic factor enhances synthesis of Arc in synaptoneurosomes.

Authors:  Yong Yin; Gerald M Edelman; Peter W Vanderklish
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

3.  The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.

Authors:  Natosha M Mercado; Jennifer A Stancati; Caryl E Sortwell; Rebecca L Mueller; Samuel A Boezwinkle; Megan F Duffy; D Luke Fischer; Ivette M Sandoval; Fredric P Manfredsson; Timothy J Collier; Kathy Steece-Collier
Journal:  Neurobiol Dis       Date:  2020-11-11       Impact factor: 5.996

4.  Nogo-A Neutralization Improves Graft Function in a Rat Model of Parkinson's Disease.

Authors:  Stefanie Seiler; Stefano Di Santo; Hans Rudolf Widmer
Journal:  Front Cell Neurosci       Date:  2016-04-05       Impact factor: 5.505

5.  Anodal Transcranial Direct Current Stimulation Enhances Survival and Integration of Dopaminergic Cell Transplants in a Rat Parkinson Model.

Authors:  Christian Winkler; Janine Reis; Nadin Hoffmann; Anne-Kathrin Gellner; Christian Münkel; Marco Rocha Curado; Luciano Furlanetti; Joanna Garcia; Máté D Döbrössy; Brita Fritsch
Journal:  eNeuro       Date:  2017-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.